Sun Pharmaceutical Industries share price slips 0.91% to ₹1,885 on November 12
Last Updated: 12th November 2026 - 07:10 pm
Key Takeaways
- Sun Pharma closed at ₹1,885, down ₹17.30 or 0.91%, after moving between ₹1,874 and ₹1,897 during the session.
- The final price remained above its 50-day, 100-day and 200-day DMAs, with the 200-day average at ₹1,817.
- The stock's one-year return stood at 9.84%, while the three-month return was negative at 2.94%.
Sun Pharmaceutical Industries share price closed November 12 at ₹1,885, losing ₹17.30 or 0.91% from the previous close of ₹1,902. The stock opened at ₹1,891, reached a high of ₹1,897 and fell to ₹1,874. Its ₹23 trading range ended with the closing price ₹11 above the low and ₹12 below the high, putting it almost exactly around the middle of the session range.
Trading volume reached 2,569,957 shares. Sun Pharma finished ₹6 below its opening price after starting the day ₹11 below the prior close. Across the previous 52 weeks, the stock had traded between ₹1,584 and ₹2,047. The November 12 close was ₹301 above the annual low and ₹162 below the high.
The final price remained above each supplied moving average. Its 50-day DMA stood at ₹1,824.20, leaving the close ₹60.80 higher. The 100-day DMA was ₹1,835.10, a difference of ₹49.90, while the 200-day DMA stood at ₹1,817. Sun Pharma therefore finished ₹68 above the longest of the three averages.
Return periods were mixed. The one-month return was 7.10%, while three-month performance stood at -2.94%. The six-month return was modestly positive at 0.66%, and the one-year result reached 9.84%. The latest closing price therefore remained above each supplied DMA even as the stock recorded a 0.91% decline for the November 12 session.
Frequently Asked Questions
What was Sun Pharmaceutical Industries share price on November 12?
Was Sun Pharma above its 200-day DMA?
What were Sun Pharma's recent returns?
- Flat ₹20 Brokerage
- Next-gen Trading
- Advanced Charting
- Actionable Ideas
Trending on 5paisa
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.